No significant difference between ceftriaxone and cefotaxime in the emergence of antibiotic resistance in the gut microbiota of hospitalized patients: A pilot study. (March 2021)

• Record Type: Journal Article
• Authors: Pilmis, Benoît; Jiang, Olivier; Mizrahi, Assaf; Nguyen Van, Jean-Claude; Lourtet-Hascoët, Julie; Voisin, Olivier; Le Lorc'h, Erwan; Hubert, Sidonie; Ménage, Elodie; Azria, Philippe; Borie, Marie-Françoise; Mahé, Annabelle; Mourad, Jean-Jacques; Trabattoni, Eloïse; Ganansia, Olivier; Zahar, Jean-Ralph; Le Monnier, Alban
• Is Part Of: International journal of infectious diseases. Volume 104(2021)
• Page Start: 617
• Page End: 623
• Publication Date: 2021-03
• Subjects: Gut microbiota -- Third generation cephalosporin -- Extended spectrum beta-lactamase; Communicable diseases -- Periodicals; Communicable Diseases -- Periodicals; Communicable diseases; Periodicals; Electronic journals; 616.9
• DOI: 10.1016/j.ijid.2021.01.025
• Languages: English
• ISSNs: 1201-9712

Abstract

Highlights: Ceftriaxone and cefotaxime affect the cultivable microbiota. Ceftriaxone and cefotaxime show equal ability to select resistant Enterobacteriaceae. No difference was found in terms of the risk of Clostridioides difficile -related infection. Abstract: Background: Ceftriaxone and cefotaxime share a similar antibacterial spectrum and similar indications but have different pharmacokinetic characteristics. Ceftriaxone is administered once daily and 40% of its clearance is by biliary elimination, whereas cefotaxime requires three administrations per day and shows less than 10% biliary elimination. The high biliary elimination of ceftriaxone suggests a greater impact of this antibiotic on the gut microbiota than cefotaxime. The objective of this study was to compare the impact of ceftriaxone and cefotaxime on the gut microbiota. Methods: A prospective clinical trial was performed that included 55 patients treated with intravenous ceftriaxone (1 g/24 h) or cefotaxime (1 g/8 h) for at least 3 days. Three fresh stool samples were collected from each patient (days 0, 3, and 7 or at the end of intravenous treatment) to assess the emergence of third-generation cephalosporin (3GC)-resistant Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, Pseudomonas aeruginosa, toxigenic Clostridioides difficile, and vancomycin-resistant enterococci. Results: The emergence of 3GC-resistant gram-negative enteric bacilli ( Enterobacteriaceae ) (5.9% vs 4.7%, p > 0.99), Enterococcus spp, and non-commensal microorganisms did not differ significantly between the groups. Both antibiotics reduced the counts of total gram-negative enteric bacilli and decreased the cultivable diversity of the microbiota, but the differences between the groups were not significant. Conclusion: No significant difference was observed between ceftriaxone and cefotaxime in terms of the emergence of resistance.